
TWST Stock Forecast & Price Target
TWST Analyst Ratings
Bulls say
Twist Bioscience is expected to see significant growth due to their disruptive DNA synthesis platform and the growing demand for AI-driven orders. With their strong focus on cost efficiency and potential for expanding DNA manufacturing capacity, the company has the potential for significant gross margin expansion and reaching Adj. EBITDA breakeven by FY26. The stock has a potential upside from current levels based on their financial targets and potential for catalysts in the near future, making it an attractive buy.
Bears say
Twist Bioscience is currently experiencing positive momentum in their stock thanks to their recent advancements in AI-driven NGS and drug discovery, but this may not accurately reflect the long-term potential for the company. There are execution risks to consider, particularly around margins and operating leverage, and the company's profitability story depends on continued gross margin improvement and disciplined expense control. Furthermore, there are potential risks from slower market growth and competition that could negatively impact the company's future performance.
This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares